Related Experiment Videos
Vulnerable atherosclerotic plaque: emerging challenge for animal models
1Department of Cardiovascular Pharmacology, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. mark.rekhter@pfizer.com
Current Opinion in Cardiology
|December 6, 2002
Summary
Developing better animal models for plaque vulnerability is crucial for acute coronary syndromes. This review discusses current models and challenges, highlighting the need for plaque-stabilizing therapies.
Area of Science:
- Cardiovascular Research
- Translational Medicine
- Atherosclerosis Research
Background:
- The clinical approach to acute coronary syndromes has spurred the development of animal models focusing on atherosclerotic plaque vulnerability.
- Understanding plaque rupture, thrombosis, and hemorrhage is critical for advancing cardiovascular disease research.
Purpose of the Study:
- To review existing animal models for studying plaque vulnerability in atherosclerosis.
- To discuss "vulnerability endpoints" used in conventional atherosclerosis models.
- To emphasize challenges in validating these animal models.
Main Methods:
- Review of literature on spontaneous and induced plaque rupture models.
- Analysis of "vulnerability endpoints" including biomechanical properties, collagen turnover, inflammation, and lipid accumulation.
- Discussion of challenges in animal model validation.
Main Results:
- Various animal models exist for studying plaque rupture, thrombosis, and hemorrhage.
- Key vulnerability endpoints provide insights into plaque instability.
- Significant challenges remain in validating these models for clinical relevance.
Conclusions:
- Current animal models offer valuable tools for investigating plaque vulnerability.
- Further development of validated models and monitoring tools is essential.
- Advancements will facilitate the design of effective plaque-stabilizing therapies for acute coronary syndromes.